MATCH SIZE AND QUANTITY
Build your comparison.
Choose a labeled amount and selection to load matching prices.
Capsule comparison
Compare BPC-157 Capsules listings by strength, selection and supplier. Inspect the original source behind each price.
MATCH SIZE AND QUANTITY
Choose a labeled amount and selection to load matching prices.
GO BEYOND THE PRICE
Select a strength and selection above to view price history, save a price watch or add it to your basket.
DOCUMENTATION PASSPORTS
Inspect the source report, recorded lot and document access. A report link does not confirm the batch currently shipping.
Loading documentation records…
Reported quantities in this family: 60. Counts and units must be matched to the exact listing.
Choose the labeled amount per unit and quantity before comparing. A single unit and a multipack have different upfront prices. Keep product format and exact recipe consistent; similar names do not establish equivalent products.
Follow the original listing to check its quantity, availability and current price. Unit prices use the full labeled mass in each selection.

122 products · 249 listings

153 products · 275 listings
2 listings from direct supplier captures. Capture and import dates record when data was obtained; they do not guarantee the supplier’s current price or stock.
Listings include out-of-stock and unconfirmed-stock records. Inclusion does not certify a supplier, a batch or a product. Read how matching and source dates work.
FROM PEPTIDES CALCULATOR
Source profile reviewed 2026-10-02 · Imported 2026-10-22. Read the full compound profile
BPC-157 (Body Protection Compound 157) is a synthetic 15-amino-acid peptide whose sequence was described by Predrag Sikiric's group at the University of Zagreb as a fragment of a protein found in human gastric juice. It has been studied almost entirely in rodent models of tendon, ligament, muscle, gut and vascular injury, where it is reported to speed healing. Human data are limited to three small pilot studies and one registered phase 1 safety trial that never posted results; it is not approved by any regulator, has been on the WADA prohibited list since 2022, and was placed in the FDA's Category 2 list of bulk substances that may present significant safety risks for compounding in 2023.
A 2025 systematic review of English-language literature identified predominantly preclinical musculoskeletal studies plus very limited human reporting, and noted the absence of strong clinical safety datasets.
Rat Achilles-tendon and tendon-to-bone experiments report improved functional and structural healing markers versus controls in those models; results do not establish human efficacy.
Cell and explant studies describe effects on tendon fibroblast outgrowth, survival under oxidative stress, and migration-related signaling pathways.
Human evidence remains sparse (small pilot / retrospective reports). No large randomized controlled trials establish clinical benefit or a settled safety profile.
Background is reproduced from Peptides Calculator with attribution. The source describes compound-level research. It does not evaluate the identity, quality or suitability of a listed supplier’s product or batch.